Research

Chloroquine and sulphadoxine-pyrimethamine sensitivity of *Plasmodium falciparum* parasites in a Brazilian endemic area

Bianca Ervatti Gama¹, Natália K Almeida de Oliveira¹, Mariano G Zalis², José Maria de Souza³, Fátima Santos⁴, Cláudio Tadeu Daniel-Ribeiro¹ and Maria de Fátima Ferreira-da-Cruz*¹

Address: ¹Laboratory of Malaria Research, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro (RJ), Brazil, ²Laboratory of Infectiology and Parasitology, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro (RJ), Brazil, ³Ambulatory and Laboratory of Malaria Clinical Assays, Secretariat of Health Vigilance, Instituto Evandro Chagas, Belém (PA), Brazil and ⁴Laboratory of Entomology, LACEN, Porto Velho (RO), Brazil

Email: Bianca Ervatti Gama - bgama@ioc.fiocruz.br; Natália K Almeida de Oliveira - nataliak@ioc.fiocruz.br; Mariano G Zalis - mngzalis@hucff.ufrj.br; José Maria de Souza - jmsouza@iec.pa.gov.br; Fátima Santos - ftsantosro@hotmail.com; Cláudio Tadeu Daniel-Ribeiro - ribeiro@ioc.fiocruz.br; Maria de Fátima Ferreira-da-Cruz* - mffcruz@ioc.fiocruz.br

* Corresponding author

Abstract

**Background:** The goal of the present study was the characterization of *Plasmodium falciparum* genes associated to malaria drug resistance (*pfcr*, *pfdhfr* and *pfdhps*), in samples from two Brazilian localities.

**Methods:** Parasites from 65 *P. falciparum* samples were genotyped using nested-PCR and direct DNA sequencing.

**Results:** Six resistant sulphadoxine-pyrimethamine (SP) *pfdhfr* genotypes and one haplotype associated to SP sensitivity were detected. For *pfcr* gene, SVMNT chloroquine (CQ)-resistant genotype was detected as well as the CVMNK CQ-sensitive haplotype in the same sample from Paragominas, that showed a SP-sensitive genotype.

**Conclusion:** This study is the first to document the sensitivity of *P. falciparum* parasites to CQ and SP in Brazilian field samples. The importance of these findings is discussed.

**Background**

Malaria is a challenging infectious disease to many countries in the world, especially to those located in tropics and subtropical regions, and the increasing numbers of drug resistant parasites worsens this situation. In Brazil, as well as in other endemic countries, drug-sensitivity tests revealed that *Plasmodium falciparum* isolates displayed high levels of resistance to many drugs, including chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) [1-4].

The first documented case of CQ resistance in Brazil was in 1954; in the sixties several authors in South America (SA) reported the occurrence of *in vivo* falciparum malaria resistance to CQ and amodiaquine. The spread of 4-amino-quinoleine resistant strains of *P. falciparum* lead also to the use of SP in the seventies. Unfortunately, at the end of eighteens the SP resistance it was no less than 90% [5] and at the beginning of nineties the CQ failure rate was considered 100% [6] and, consequently, the Brazilian
National Malaria Programme withdrew SP and CQ for falciparum malaria treatment. Then, the combination quinine plus tetracycline was introduced, followed by the usage of the combination quinine plus doxycycline or, as second-line drug, mefloquine plus primaquine. In 2007, a fixed combination of artemether plus lumefantrine (Coartem®) was introduced as first-line drug [7] and since 2008, the fixed combination artesunate plus mefloquine (FarManguinhos, Fiocruz) was produced, and its implementation in Brazilian endemic areas is in progress to counteract parasite resistance, according to WHO guidelines [8].

Interestingly, the reemergence of CQ-sensitive P. falciparum parasites as well as the downturn of P. falciparum triple mutants associated to SP resistance, were reported after cessation of monotherapy using CQ or SP for the treatment of P. falciparum malaria [9-13]. These findings provide a rationale for the search of drug-sensitive haplotypes in P. falciparum isolates in Brazilian areas where the use of these two drugs for falciparum malaria treatment has been interrupted since 1990.

The goal at the present study was, therefore, the characterization of pfcrt, pfldhfr and pfldhps genes that are known molecular markers of P. falciparum resistance to CQ and SP [14].

Methods

Study sites, blood samples and DNA extraction

Parasites from 65 P. falciparum samples were genotyped. These samples were collected at the time of diagnosis from uncomplicated malaria patients living in two Brazilian malaria-endemic areas: Porto Velho – Rondônia state (n = 46), and Paragominas – Pará state (n = 19). After obtaining the informed consent, venous blood collection was done according to protocols previously approved by the ethics research committees of Fiocruz and of local study sites. DNA was extracted from 1 ml of cryopreserved blood using QIAamp midi columns as described by the manufacturer (Qiagen).

Polymerase chain reactions (PCRs) and electrophoresis

A nested-PCR technique was employed in order to amplify a partial DNA sequence containing the major single-nucleotide polymorphisms (SNPs) related to drug-resistance for each target gene as: SNPs A16V/S, C50R, N51I, C59R, S108N, V140L plus I164L for pfcrt gene, three single haplotypes (SGEGA, SGEAA, SGKAA), displaying up to three (437G + 540E and 581G) out of the five SNPs analysed were observed and, in this case, no drug sensitive haplotype (SAKAA) was detected. In relation to pfcrt gene, two single haplotypes were observed: the SVMNT CQ-resistant in 97% of the samples and the CVMNK CQ-sensitive in the same sample from Paragominas locality, associated with SP sensitivity (ACICNVI). The drug resistance pfldhfr haplotypes displayed up to three (50R + 51I and 108N; 51I + 108N and 164L, or 51I + 59R and 108N) out of seven SNPs herein analysed. Concerning the pfldhps gene, three single haplotypes (SGEGA, SGEAA, SGKAA), displaying up to three (437G + 540E and 581G) out of the five SNPs analysed were observed and, in this case, no drug sensitive haplotype (SAKAA) was detected. In relation to pfcrt gene, two single haplotypes were observed: the SVMNT CQ-resistant in 97% of the samples and the CVMNK CQ-sensitive in the same sample from Paragominas that showed the sensitive genotype to SP (pfldhfr gene). All the three genes displayed at least one mixed haplotype. These results are summarized in Table 1.

A multilocus analysis among the 47 samples showing single haplotypes was performed. The pfldhfr + pfldhps + pfcrt genes presented some usual haplotype associations as, respectively, follows: ARICNV1 + SGEGA + SVMNT (42.5%), ACICNV1 + SGEAA + SVMNT (27.6%), ARIC-
NVI + SGEAA + SVMNT (10.6%), ACICNVI + SGEAA + SVMNT (6.3%) and ACICNVI + SGEAA + SVMNT (4.2%). Other combinations such as ACICNVI + SGEAA + SVMNT (2.13%), ACNCNVI + SGEGA + SVMNT (2.13%), ACNC-SVI + SGEAA + SVMNT (2.13%) and ACNRNVI + SGKAA + SVMNT (2.13%) were observed only once. In all these samples \textit{pfhdhfr} and \textit{pfhdps} haplotypes were significantly associated (p < 0.0001, Chi-square test); the same was true for the only \textit{P. falciparum} sample with CQ and SP sensitive genotypes.

The five amino acid insertion between codons 30 and 31 of the \textit{pfhdfr} gene named "Bolivia repeat" was found in 17 samples (one from Paragominas and 16 from Porto Velho) and it was always associated with the leucine at the codon 164, as previously reported [17].

In the two studied localities, the prevalence of the haplotypes was different, for \textit{pfhdfr}, \textit{pfhdps} and \textit{pfcr}t genes, respectively. In Paragominas the predominant haplotypes were ARICNVI, SGEGA and SVMNT while in Porto Velho, the main ones were ACICNVL, SGEGA and SVMNT.

**Discussion**

Porto Velho displayed more allelic variation than Paragominas, especially for the \textit{pfhdps} gene. No previous studies were performed with \textit{P. falciparum} samples from Paragominas, but two former studies had been performed in Porto Velho using SP [2] or CQ [18] molecular markers. In these reports, the authors detected the haplotypes CVIET (\textit{pfcr}t gene), AEGEA (\textit{pfhdps} gene) and the S108T (\textit{pfhdfr} gene) that were not seen in the present study. However, \textit{pfhdps} and \textit{pfhdfr} haplotypes such as SGEAA, SGKAA,
ACIRNVI and ACNRRNVI, were described for the first time in Brazil, while they had only previously been reported from Tanzania [15] and India [19]. This might be due to the considerable human movement in Porto Velho, not only from other Amazonian (SA) regions, but also from other areas in and outside Brazil, which could also explain the detection of 16 P. falciparum infections harbouring the "Bolivia repeat" against only one identified in Paragominas.

In Venezuela, a pfcrt wild type, similar to that found in Paragominas, was also detected [20]. Differently from Porto Velho, migration from the city of Paragominas to other SA countries is very uncommon and, therefore, the existence of a wild type parasite in Brazil seems not to be related to parasite migration from other SA countries. Since this infection harboured wild-type codons at pfcrt 72, 74, and 75, it is less probable that this haplotype correspond to a single resistant allele that would have reverted at the critical 76 codon (back mutation) and, consequently, the more plausible explanation for this finding is the presence of a bona fide sensitive allele.

Interestingly, in this study, an inferior prevalence of mutated codons associated to SP resistance was perceived when compared pfdhps haplotypes with those already observed in Brazil [2]. For instance, in 1998, Porto Velho isolates displayed triple (53.4%) or quadruple (46.6%) mutants in this gene, while single (22.7%), double (18.2%) and triple (54.5%) mutants were detected in this study, but no quadruple mutation was identified.

The present study is the first to document the existence of CQ (CVMNK) and SP (ACNCNSVI) sensitive haplotypes in a Brazilian field sample. This is a noteworthy result, because in Brazil the totally of P. falciparum parasites were considered to be fully resistant to CQ and SP [18]. This fact was not, however, surprising since the same phenomenon had already been reported in China and Malawi [9-11]. Then, it could represent the reemergence of CQ and SP sensitive parasites probably due to the spread of wild type allele P. falciparum parasites [21]. Despite the relatively small number of samples, it is suggested that the number of sensitive parasite population detected remains low because CQ is currently still used for the treatment of malaria vivax cases and SP or its analogues, are used for anti-microbial therapy and, in this way, Plasmodium parasites could still be under drug pressure.

The finding of a single wild SP and CQ isolate will not interfere in drug policy, but this detection is especially remarkable because it might represent a tendency of sensitive haplotypes re-emergence that could gain some importance in the future.

Conclusion
These data reinforce the importance of performing molecular surveillance by continuous chemoresistance assessment, not only to predict shifts of drug resistance of Plasmodium populations following drug policy changes but, particularly, to investigate the possibility of reintroduction of anti-malarial drugs, such as CQ and SP, because of their low cost and wide availability. In this context, the critical problem of P. falciparum chemoresistance could be circumvented by turning-over the use of the drugs, in order to enable the re-emergence of wild sensitive parasites.

Abbreviations
pfcrt: Plasmodium falciparum chloroquine resistance transporter; pfdhfr: Plasmodium falciparum dihydrofolate reductase; pfdhps: Plasmodium falciparum dihydropteroate synthase; DNA: deoxyribonucleic acid; PCR: polymerase chain reaction; SNPs: single-nucleotide polymorphisms; CQ: chloroquine; SP: sulphadoxine-pyrimethamine.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
BEG participated in the design of the study, carried out the molecular analysis and drafted the manuscript; NKAO performed the PCR assays; MGZ performed the pfcrt-PCR standardization; JMS and FS helped in design of the study and field facilities for blood sample collections; CTD helped in the design of the study and reviewed the manuscript; MFFC conceived the study, coordinated its design, and finalized the manuscript. All authors have read and approved the final text.

Acknowledgements
We are deeply grateful to Paulo Renato Rivas Totino, Evelyn Kety Pratt Riccio, Lilian Rosa Pratt Riccio and Clarissa Perez Faria that kindly provided blood samples for this study. We would also like to thank the staff from the Genomic Platform/PDTIS/Fiocruz.

This work was financially supported by POM/PEF/Instituto Oswaldo Cruz and CNPq/PAPES-Fiocruz, FAPERJ and CAPES programs (Brazil).

References
1. Zalis MG, Pang L, Silveira MS, Milhous WK, Wirth DF: Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: evidence for quinine resistance. Am J Trop Med Hyg 1998, 58:630-637.
2. Vasconcelos KF, Plowe CV, Fontes CJ, Kyle D, Wirth DF, Pereira da Silva LH, Zalis MG: Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. Mem Inst Oswaldo Cruz 2000, 95:721-728.
3. Alecrim WD, Dourado H, Alecrim M, das G, Passos LF, Wanssa E, Albuquerque B: In vivo resistance of Plasmodium falciparum to the combination of sulfadoxine and pyrimethamine, at RIII level, in Amazonas, Brazil. Rev Inst Med Trop Sao Paulo. 1982, 24(6 Suppl):52-53.
4. da Silva J, Lopes PF, Ferreira LF, Morteo R, Navieira JB: Resistance of Plasmodium falciparum to the action of chloroquine. Hospital (Rio J), 1961, 60:581-594.

5. Souza JM: Epidemiological distribution of Plasmodium falciparum drug resistance in Brazil and its relevance to the treatment and control of malaria. Mem Inst Oswaldo Cruz 1992, 87:343-348.

6. Andrade JG, Andrade AL, Araujo ES, Oliveira RM, Silva AS, Martelli CM, Zicker F: A randomized clinical trial with high dose of chloroquine for treatment of Plasmodium falciparum malaria in Brazil. Rev Inst Med Trop Sao Paulo 1992, 34(5):467-473.

7. Camargo LMA, Oliveira S, Basano S, Garcia CRS: Antimalarials and the fight against malaria in Brazil. Vasc Health Risk Manag 2009, 5:1-7.

8. WHO: Malaria treatment update. [http://www.who.int/malaria/rbm/Attachment/20041108/pr8nov2004.htm].

9. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, Tsukahara T, Tarabe K, Kobayakawa T, Björkman A: Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg 2003, 68:413-415.

10. Kublin JG, Cortese JF, Njunju EM, Mckadam RA, Wiruma JJ, Kazembe TN, Tanahe K, Kuriba B, Taylor TE, Plowe CV: Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 2003, 187:1870-1875.

11. Wang X, Mu J, Li G, Chen P, Guo X, Fu L, Chen L, Su X, Wellemes TE: Decreased prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against P. falciparum malaria in Hainan, People's Republic of China. Am J Trop Med Hyg 2005, 72:410-414.

12. Zhou Z, Griffing SM, de Oliveira AM, McCollum AM, Quezada WM, Arroyso N, Escalante AA, Udhayakumar V: Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru. Antimicrob Agents Chemother 2008, 52:739-741.

13. Bacon DJ, McCollum AM, Griffing SM, Salas C, Soberon V, Santollalla M, Haley R, Tsukayama P, Lucas C, Escalante AA, Udhayakumar V: Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria. Antimicrob Agents Chemother 2009, 53:2042-2051.

14. Talisuna AO, Bloland P, D'Alessandro U: History, dynamics and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004, 17:235-254.

15. Pearce RJ, Drakeley C, Chandramohan D, Moshf F, Roper C: Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother 2003, 47:1347-1354.

16. Otto TD, Vacconcellos EA, Gomes LHF, Moreira AS, Degreve WM, Mendonça-Lima L, Alves-Ferreira M: ChromaPipe: a pipeline for analysis, quality control and management for a DNA sequencing facility. Genet Mol Res 2008, 7:861-871.

17. Plowe CV, Cortese JF, Djimde A, Nyawayo OC, Wadkins WM, Winsten PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbou OK: Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997, 175:1590-1596.

18. Vieira PP, Ferreira MU, Alecrim MG, Alecrim WD, da Silva LH, Silhuincha MM, Joy DA, Mu J, Su XZ, Zalis MG: PfCRT polymorphism and the spread of chloroquine resistance in Plasmodium falciparum populations across the Amazon Basin. J Infect Dis 2004, 190:417-424.

19. Ahmed A, Bararia D, Vinayak S, Yameen M, Biswas S, Dev V, Kumar A, Ansari MA, Sharma YD: Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance. Antimicrob Agents Chemother 2004, 48:879-889.

20. Contreras CE, Cortese JF, Caraballo A, Plowe CV: Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar. Am J Trop Med Hyg 2002, 67:400-405.